15 min read
June 30, 2026
You are not buying code. You are buying something that has to survive an FDA inspection, a SOC 2 audit, or a covered entity's security review — often all three.
Most vendor-evaluation advice was written for buyers comparing finished products, and it transfers badly when the thing you're selecting is a team that will build under regulation.
A healthcare software vendor evaluation checklist should verify four things:
The distinction matters because most of what passes for due diligence in this field is theater. "We're HIPAA compliant" gets accepted as an answer. It isn't one.
This checklist is built for the harder question: can a vendor show you the evidence, or only describe it?
Choosing a healthcare software partner?
We've shipped 30+ healthcare products with zero failed audits.
Why healthcare software vendor evaluation is different
A bad vendor choice costs you time and money. In regulated healthcare, it costs you those plus your compliance posture and, sometimes, your architecture.
Compliance is not a feature you add before launch. It is a set of decisions made on the first day of design — where PHI lives, how it moves, who can touch it, how every change is recorded. A vendor who treats HIPAA, GDPR, or 21 CFR Part 11 as a pre-launch step will hand you a system that has to be partly rebuilt to satisfy an auditor. That rework is the expensive kind, because it touches data models and audit trails, not UI.
Two readers arrive here. One is buying a finished product — an EHR, a clinical-communications tool — and needs criteria centered on the deployed system. The other is deciding how to choose a healthcare software development vendor to build, test, or modernize under regulation. This checklist is written for the second reader. If you're buying a product, most of what follows still applies, but your strongest signal is references from organizations like yours running the system in production.
Custom healthcare software vendor selection criteria that matter most are the ones a vendor cannot fake on a sales call. Everything below is chosen for that reason.
"HIPAA compliant" is not a checkbox
Start with the correction that separates a serious evaluation from a ceremonial one: there is no HIPAA-certified software.
HHS does not certify, approve, or register software products. No government body issues a HIPAA compliance badge. When a vendor says "we're HIPAA compliant," they are describing an intention, not a credential — and a HIPAA compliant vendor checklist that accepts the claim at face value has verified nothing.
What you can assess is narrower and more useful. HIPAA's Security Rule defines technical safeguards under 45 CFR §164.312 — access controls, audit controls, integrity controls, authentication, and transmission security. A vendor either implements these in specific, describable ways or they don't. Ask how each one is built. "We encrypt data at rest and in transit" is a starting point; "audit controls log every access to a PHI record with user, timestamp, and action, retained and tamper-evident" is an answer.
The second non-negotiable is a signed Business Associate Agreement. If a vendor will handle PHI on your behalf and resists signing a BAA, the evaluation is over. The BAA binds them to the safeguards and makes breach obligations enforceable. Treat the business associate agreement checklist as table stakes: signed before any PHI touches their systems, with breach-notification timelines and subcontractor flow-down spelled out.
Software supports your compliance. It cannot certify it. A vendor who understands that distinction is already ahead of most.
The core healthcare software vendor evaluation checklist
Below is the checklist itself, in four areas. None of it is exotic. The difference between a useful evaluation and a ceremonial one is whether you press each question until you get a specific answer or a vague one.
Compliance and data handling
Start with the data, because the data is what's regulated. Map the full PHI lifecycle: where it's created, stored, transmitted, backed up, and destroyed. Confirm encryption at rest and in transit, and ask which approach to key management — "we use encryption" is not a control description.
Review access controls: role-based, least-privilege, and logged. Confirm the BAA covers every subcontractor that could touch PHI. For products under GDPR, confirm a lawful basis and how data residency is handled.
Technical and integration
The strongest single predictor of a healthcare build succeeding is prior EHR-integration track record. Integration is where these projects stall — mismatched HL7 v2 feeds, FHIR resources that don't map cleanly, DICOM workflows that behave differently across modalities.
Ask for specific integrations the vendor has shipped: which EHRs, which standards, what broke, how they fixed it. A vendor with real HL7 FHIR integration vendor experience answers in particulars. One without it answers in brochures. Probe scalability against your actual load, not a generic "we scale."
Engineering and QA
Ask where QA sits. The answer tells you most of what you need to know. If quality assurance means developers reviewing their own code, you have no independent verification — and in regulated software, independent V&V is the point. Look for dedicated QA engineers who understand healthcare data, not generalists who learned the domain last quarter.
For medical device software, QA validation is a regulated activity, not a courtesy. And for any system that moves or transforms PHI, ask specifically how they prove no record is lost, corrupted, or mis-mapped across a migration or an integration. That evidence is what a regulator asks to see.
Commercial
Get references from organizations like yours — same regulatory regime, similar scale. Ask about update cadence and how the vendor handles a change to a validated system without re-opening the whole validation.
Confirm support model and response times in writing. Settle exit terms before you sign: data-return format, transition support, and IP ownership. A vendor confident in the relationship makes leaving easy.
HIPAA safeguards
Maps each §164.312 control to a specific implementation
"We're fully HIPAA compliant"
BAA
Signed before PHI access; subcontractor flow-down included
"We can sign one if you really need it"
EHR integration
Names specific EHRs and standards shipped, including what failed
"We can integrate with anything"
QA structure
Independent QA engineers with healthcare domain experience
"Our developers test their own work"
Data-transformation testing
Shows how record integrity is proven across migrations
"We do standard testing"
References
Clients in the same regulatory regime, reachable
"We can't share clients for confidentiality"
Exit terms
Data return and transition support defined up front
"We'll figure that out later"
The Evidence Test: 9 artifacts a compliant vendor produces in 48 hours
Every competitor's checklist lists questions to ask. This one lists documents to request — because the gap between a vendor who says the right things and one who can prove them shows up the moment you ask for evidence.
A serious regulated-healthcare vendor already has these artifacts. They are the routine output of building under IEC 62304, ISO 13485, or 21 CFR Part 11 — not deliverables a vendor scrambles to assemble. Ask for them and watch the response. A real one shares redacted versions in a day or two. A compliance-washed one needs "a few weeks to pull that together," which means the documents don't exist yet.
Here is what to request.
Requirements traceability matrix — links requirement → design → test → result. It is the spine of IEC 62304 and FDA expectations. Without it, a vendor cannot prove any feature was tested against the requirement it exists to satisfy.
V&V protocols and reports — verification asks whether they built it right; validation asks whether they built the right thing. A vendor who uses the two words interchangeably is telling you they don't do one of them.
21 CFR Part 11 audit-trail and e-signature design note — for products touching FDA-regulated electronic records. It shows how the system records who did what and when, and how it prevents unattributed change. This is where a 21 CFR Part 11 compliance evaluation either holds up or collapses.
Risk management file — ISO 14971 thinking applied to the product: hazards identified, risk estimated, controls documented. For anything classed as SaMD, this is where development partner requirements begin.
SOC 2 Type II report — the report, not the certificate. It covers a defined testing period and lists exceptions. The certificate says they were assessed; the report says what was found.
HL7 FHIR / DICOM conformance test evidence — proof the integrations conform, not a sentence claiming support.
Defect / CAPA log — how issues are tracked, triaged, and closed. It shows whether quality is managed or improvised.
Change-control / configuration-management procedure — how changes to a validated system are controlled, so one fix doesn't quietly invalidate the whole validation.
Penetration test summary with remediation status — findings and what was done about them. An old test with open criticals is worse than no test, because it documents a known, unaddressed risk.
Requirements traceability matrix
No proof any feature was tested against a requirement
V&V protocols and reports
Verification and validation are conflated or skipped
21 CFR Part 11 audit-trail design note
Electronic records may not withstand FDA inspection
Risk management file (ISO 14971)
Hazards for a SaMD product were never formally assessed
SOC 2 Type II report (not the cert)
Security controls were never tested over time
FHIR / DICOM conformance evidence
"We support it" has never been verified
Defect / CAPA log
Quality issues are handled ad hoc, not tracked to closure
Change-control procedure
A single change can silently break a validated state
Pen-test summary with remediation
Security posture is unknown or unaddressed
We hold this standard internally. Across 16 years and 30-plus regulated products, Flyant's record is zero failed regulatory audits — which is only possible when the evidence exists before anyone asks for it.
The 48-hour expectation is not a clause to extract from a contract. It is a diagnostic. Serious vendors don't build these documents on request. They maintain them, because the regulator could ask tomorrow.
Red flags that should end the conversation
Some answers should end the evaluation, not lower its score. These are the healthcare vendor red flags that no amount of good chemistry offsets.
"We're HIPAA compliant," offered as a complete answer. You now know why. If pressing for the safeguards behind §164.312 produces reassurance instead of specifics, the vendor either doesn't know them or doesn't have them.
No independent QA. If the people testing the software are the people who wrote it, there is no independent verification — and for regulated software, V&V independence is not optional. "Our developers are very thorough" is not a QA function.
Your project is their first healthcare integration. Integration is where timelines die. If a vendor will be learning HL7 FHIR or DICOM on your budget and your deadline, you are paying for their education and absorbing the schedule risk. Ask directly: have you shipped this integration before, or will ours be the first?
Certificates offered, reports refused. A vendor will happily email a SOC 2 logo or an ISO 13485 certificate. The Type II report — the one with the testing period and the exceptions — is the document that matters. "We can't share the full report" on a properly NDA'd request usually means the report says something they'd rather you not read.
None of these is a negotiation point. Each is a structural fact about how the vendor works.
From audit gap to real cost
A proper healthcare software vendor risk assessment traces consequences, not just probabilities. Here is the chain that turns a documentation gap into money.
A design decision gets made in a sprint — a change to how a SaMD product calculates a dosing threshold, say — and nobody links it back to a requirement or forward to a test. Months later, the submission is in review. An auditor asks for the traceability from that requirement to its verification. It isn't there.
Now the work begins. The team reconstructs the rationale, re-runs verification, and rebuilds the traceability after the fact. The submission pauses. If the gap surfaces a week before a planned submission, the planned date is gone. Every week of delay is a week of burn against a runway that was sized for a launch, plus the cost of a market window that doesn't wait.
The undocumented decision cost nothing to make and a quarter to fix.
This is why on-budget delivery and a clean audit record are the same discipline, not two. A vendor who documents design decisions as they go — because IEC 62304 and Part 11 expect it — produces evidence as a byproduct of building. A vendor who treats documentation as a phase produces it under deadline pressure, which is exactly when it comes out incomplete. The first vendor lands on budget more often, because rework is the largest unplanned cost in regulated software, and traceability is what prevents it.
How to run the evaluation
Turn this into a scorecard, but weight it for what's actually at risk. For a regulated product, compliance evidence and QA independence should carry more weight than price or even timeline — because those are the criteria that survive an audit. A weighted grid that treats "cultural fit" and "traceability matrix on request" as equal line items will mislead you.
Run the evaluation with the right people in the room.
Clinical stakeholders judge whether the system fits real workflows.
Technical leaders test the integration and architecture claims.
Procurement holds the commercial and exit terms.
Compliance or quality leadership reads the artifacts — they're the ones who'll defend them later.
The healthcare outsourcing vendors worth signing tend to share a trait: engineering and QA aren't two functions handing work back and forth, and compliance was designed in from the first sprint rather than retrofitted before launch.
That's the model Flyant is built on — healthcare-fluent engineers and quality engineering and test automation operating as one team, with a record of zero failed regulatory audits across 30-plus regulated products.
Ask for the evidence before you sign. The vendors who can show it are the ones who were going to pass your audit anyway.
One function. One trace. No seam.
Engineering and QA under one contract, one owner — the traceability matrix stays current as requirements move.
Frequently Asked Questions
Didn’t find the answer you are looking for?
Contact usAnastasiia Sokolinska is the Chief Operating Officer at Flyant, responsible for operational strategy, delivery performance, and scaling QA services for complex healthcare software products. She leads operations across QA and software delivery, building teams and processes that hold up as products grow, with a focus on delivery predictability and process maturity at every stage.
